A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

PHASE3TerminatedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

June 7, 2023

Study Completion Date

June 7, 2023

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Reldesemtiv

Oral tablet

Trial Locations (41)

9

RSCI Education and Research Center Beaumount Hospital, Dublin

2139

Concord Repatriation General Hospital, Concord

3000

Uz Leuven Gasthuisberg Department of Neurology, Leuven

3584

UMC Utrecht Department of Neurology, ALS Center, Utrecht

4029

Royal Brisbane and Women's Hospital, Neurology Department, Herston

6009

The Perron Institute, Nedlands

10021

Hospital for Special Surgery, New York

10126

"AOU Citta della Salute e della Scienza di Torino Universita degli Studi di Torino P.O. Mollinette - Dipartimento de Neuroscienze Rita Levi Montalcini", Torino

13210

SUNY Upstate Medical University Institute for Human Performance, Syracuse

20037

George Washington Medical Faculty Associates, Washington D.C.

20149

IRCCS Istituto Auxologico Italiano Ospedale San Luca U.O. Neurologia e Stroke Unit, Milan

21287

Johns Hopkins Outpatient Center, Baltimore

23233

Virginia Commonwealth University, Henrico

28016

Hospital San Rafael, Madrid

28207

Atrium Health Neuroscience Institute, Charlotte

32209

University of Florida, Jacksonville

32224

Mayo Clinic Jacksonville, Jacksonville

33612

University of South Florida - Carol and Frank Morsani Center for Advanced Health Care, Tampa

43202

Indiana University IU Health Neuroscience Center, Indianapolis

44195

Cleveland Clinic, Cleveland

46026

Hospital Universitario y Politecnico La Fe, Valencia

48109

Michigan Medicine, Ann Arbor

48202

Henry Ford Hospital, Detroit

53226

Froedtert Hospital - Department of Neurology, Milwaukee

66160

The University of Kansas Medical Center, Kansas City

68506

Neurology Associates, Lincoln

75206

Texas Neurology, P.A., Dallas

80045

University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora

85013

St. Joseph's Hospital & Medical Center - Barrow Neurological Institute, Phoenix

92868

University of California Irvine - ALS & Neuromuscular Center, Orange

94109

California Pacific Medical Center - Forbes Norris MDA/ALS Research Center, San Francisco

T2N 4Z6

University of Calgary - Heritage Medical Research Clinic, Calgary

T6G1Z1

University of Alberta, Edmonton

E3B 0C7

Stan Cassidy Centre for Rehabilitation, Fredericton

L8N4K1

McMaster University, Hamilton

K1Y4E9

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

S7K0M7

University of Saskatchewan, Saskatoon

G1J1Z4

CHU de Quebec-Universite Laval, Québec

113 61

Studieenheten, Akademiskt Specialistcentrum, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cytokinetics

INDUSTRY

NCT05442775 - A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) | Biotech Hunter | Biotech Hunter